Sanofi-aventis presented its new research and development model project. The model, which aims to transform R&D and increase innovation, is the first pillar of the Group's new strategy which was presented in February 2009 by Christopher A. Viehbacher, chief executive officer of sanofi-aventis.
Pharma major Lupin has acquired the global rights for an intra-nasal steroid (INS) product, AllerNaze. The Mumbai-based company has acquired the rights from Collegium Pharmaceuticals , a mid-size innovator company in the US, it announced in a release on Tuesday.
Zila, Inc has entered into a definitive merger agreement with Tolmar Holding, Inc, a privately held, pharmaceutical research, development, manufacturing and commercial operations company.
Piramal Healthcare Ltd is expanding its contract manufacturing services to early phase business, offering supplies of clinical trial quantities both in active pharmaceutical ingredient (API) and formulation segments.
Pharma firm Wockhardt will be selling its Animal Health Division to France-based Vetoquinol for an estimated Rs 170 to 180 crore.
A couple of years ago, the CEO of a leading European multinational drugmaker had notoriously called Indian pharmaceutical companies 'thieves', for making copycat versions of innovator drugs.
Japan-based pharmaceutical company Astellas Pharma announced its plans to foray into the Indian market and establish its business in the country by developing sales and marketing infrastructure for its products base.
Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, and Chugai Pharmaceutical Co., Ltd., a leading Japanese research-based pharmaceutical company, have signed a multi-year contract for the use of the Genedata Expressionist® system to streamline their internal R&D process.
Biocon has entered into a definitive agreement with Mylan Inc, for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace.
The National Pharmaceutical Pricing Authority (NPPA) has issued notices to 22 pharma companies across the country in the last three months seeking explanation for violating the price regulation by selling drugs in higher than the prices fixed by the authority.
GlaxoSmithKline (GSK) announced that the Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK's product Seretide, an inhaled respiratory treatment for asthma and COPD.
Multinational drug makers seem hell bent upon forcing the government to alter the patent regulations in their favour.
Union government is formulating a policy for traceability in packaging for the pharmaceutical sector. The traceability norms are expected to put an end to the undesirable use of recycled bottles by the pharmaceutical companies.
Move over off-patent chemical drugs. It's the now the turn of off-patent drugs of bacterial, or mammalian, origins to attracting the attention of the pharmaceutical industry.
British companies are looking to partner with Indian clinical research organisations (CROs) in a bid to tap the $1 billion (about Rs 4,800 crore) clinical research market in India. This is on the back of growth in Europe having stagnated.
Once despised as a ‘dirty business’, generics are now seen as salvation, and Indian cos as experts.
Elder Pharmaceuticals has signed an agreement with US-based MD Anderson Cancer Center to conduct human experiments for its newly-discovered anti-cancer drug.
Talking about the outlook for the pharmaceutical industry in India, KRN Moorthy, Deputy Managing Director, Wanbury said that the pharmaceutical industry should do well in the coming years.
Quick on the heels of a setback to divest its hospital chain to Apollo Hospitals, troubled Indian drugmaker, Wockhardt Ltd, which has debt of Rs3, 400 crore as on 31 December 2008, has succeeded in selling its German unit Esparma to Mova Pharma, the company announced yesterday.
After multinational drugmakers, it's the European Union's (EU) turn to exert pressure on India to agree to provisions that could affect the registration and availability of low-cost medicines.